About the SCVI Biobank

The Stanford Cardiovascular Institute (SCVI) Biobank, funded in part by NIH/NHLBI and CIRM, is compiling a biorepository of patient specific, de-identified human induced pluripotent stem cell (iPSC) lines. Patients cover a broad spectrum of cardiac diseases, healthy controls, and non-cardiac disease controls.  

Patients consent to a simple blood draw, after which we isolate the peripheral blood mononuclear cells (PBMCs) and reprogram to iPSCs. We use current, non-integrating techniques to reprogram new patient lines. Single nucleotide polymorphism (SNP) analysis is used to match iPSC lines to the original patient cells and provide karyotype information about each line. Pluripotency and tri-lineage differentiation are confirmed using the TaqMan® hPSC Scorecard™ Assay. 

In addition to Stanford patients, we recruit patients from external institutions. These patients sign the Stanford consent form, after which their blood can be collected and spun down at your institution and shipped to the SCVI Biobank. We will confirm the consents, reprogram the cells and ship the iPSC lines back to you after validation. Please click here for detailed information and requirements for including your patients in the SCVI Biobank.

For more information contact:

Joseph C. Wu, MD, PhD

Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Cardiovascular Medicine & Radiology


Karim Sallam, MD

Clinical Assistant Professor

SCVI Biobank Co-Director


Yan Zhuge, PhD

SCVI Biobank Manager